New MRI contrast agent developed for imaging liver tumors

14:23 EDT 4 May 2017 | TriMed Media Group

Liver cancer may face a formidable new adversary in the form of a novel MRI contrast agent that, in preclinical experiments, has shown its ability to wring clear tumor images from both T1- and T2-weighted MRI scans.

Developed at the National University of Singapore (NUS), the dual-mode dye incorporates nanodiamond technology, according to a news item produced by the school and published in Lab Manager.

The principle investigator behind the substance’s development, Edward Chow, PhD, says his team hopes their nanomedicine advancement will lead to liver imaging that is both safer and more accurate than current modes.

“Moving forward, we plan to conduct further preclinical safety studies for our contrast agents, with the end goal being clinical implementation,” he adds.

Chow says they’re also looking into applications for glioma and ovarian cancer.

Read the item: 

Author Reference: 
Content Type: 
Top Story: 

Original Article: New MRI contrast agent developed for imaging liver tumors


More From BioPortfolio on "New MRI contrast agent developed for imaging liver tumors"

Quick Search

Relevant Topics

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Radiology is the branch of medicine that studies imaging of the body; X-ray (basic, angiography, barium swallows), ultrasound, MRI, CT and PET. These imaging techniques can be used to diagnose, but also to treat a range of conditions, by allowing visuali...